Impact on health outcome and costs of influenza treatment with oseltamivir in elderly and high-risk patients

References

• Cox NJ. Influenza. Lancet 1999; 354: 1277–1282.
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. London: Blackwell Science Ltd, 1998.
   Google Scholar
• Nicholson KG. Clinical features of influenza. Seminars in Respiratory Infections 1992; 7: 26–37.
   Google Scholar
• Cate TR. Clinical manifestations and consequences of influenza. American Journal of Medicine 1987; 82 (Suppl 6A): 15–19.
   Google Scholar
• Buchman CA, Doyle WJ, Skoner DP. Influenza A virus – induced acute otitis media. Journal of Infectious Diseases 1995; 172: 1348–1351.
   PubMedGoogle Scholar
• Togashi T, Matsuzono Y, Narita M. Epidemiology of influenza-associated encephalitis-encephalopathy in Hokkaido, the northernmost island of Japan. Pediatrics International 2000; 42: 192–196.
   PubMed Web of Science ®Google Scholar
• Perrotta DM, Decker M, Glezen WP. Acute respiratory disease hospitalization as a measure of impact of epidemic influenza. American Journal of Epidemiology 1985; 122: 468–476.
   PubMed Web of Science ®Google Scholar
• Menec VH, Black C, MacWilliam L et al. The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality. Canadian Journal of Public Health 2003; 94: 59–63.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2002; 51(RR-04): 1–31.
   Google Scholar
• Cianci C. Development of antivirals against influenza. Expert Opinion on Investigational Drugs 1998; 7: 149–165.
   PubMedGoogle Scholar
• Fleming D. Managing influenza: amantadine, rimatadine and beyond. International Journal of Clinical Practice 2001; 55: 189–195.
   PubMedGoogle Scholar
• Kim CU, Lew W, Williams MA. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocylic sialic acid analogues with potent anti-influenza activity. Journal of the American Chemical Society 1997; 119: 681–690.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Roberts NA. In-vitro and in- vivo efficacy of influenza neuraminidase inhibitors. Current Opinion in Infectious Diseases 1998; 11: 727–732.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Treanor JJ, Fritz RS et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. Journal of the American Medical Association 1999; 282: 1240–1246.
   Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. Journal of the American Medical Association 2000; 283: 1016–1024.
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845–1850.
   Google Scholar
• Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and compromised for infectivity and replicative ability in vivo. Antiviral Research 2002; 54: 79–88.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. London, 2003. Available at: http://www.nice.org.uk/pdf/58_Flu_full guidance.pdf
   Google Scholar
• Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. European Journal of Clinical Microbiology and Infectious Diseases 2000; 19: 834–842.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guidance for manufacturers and sponsors. Technological Appraisals Process Series 5. London, 2001.
   Google Scholar
• Stouthard M. Disability weights for diseases in the Netherlands. Department of Public Health, Erasmus University Rotterdam, Rotterdam, The Netherlands, 1997.
   Google Scholar
• Simonsen L, Fukuda K, Schonberger LB et al. The impact of influenza epidemics on hospitalizations. Journal of Infectious Diseases 2000; 181: 831–837.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association 2003; 289: 179–186.
   PubMed Web of Science ®Google Scholar
• Die Spitäler der Schweiz. H+ Spitalstatistiken, Medizinische Gesamtstatistik der Schweizer Spitäler 1996. H+ Verlag CH-5001 Aarau, 1997.
   Google Scholar
• Bochud PY, Moser F, Erard P et al. Community-acquired pneumonia. A prospective outpatient study. Medicine (Baltimore) 2001; 80: 75–87.
   PubMed Web of Science ®Google Scholar
• Sander B, Gyldmark M. Impact of different methods of QALY calculations on CUA results and decision-making – the case of influenza treatment with neuraminidase inhibitors. [Oral presentation] 4th World Conference of the International Health Economics Association, San Francisco, June 2003.
   Google Scholar
• The European Agency for the Evaluation of Medicinal Products. European Public Assessment Report (EPAR): Summary of product characteristics. Available at: http://www.eudra.org/humandocs/ Humans/EPAR/tamiflu/tamiflu.htm
   Google Scholar
• Turner D, Wailoo A, Nicholson K et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. NICE Assessment Report, 2002
   Google Scholar
• Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Archives in Internal Medicine 2003; 163: 1667–1672.
   PubMed Web of Science ®Google Scholar
• Netten A, Rees T, Harrison G. Unit costs of health and social care. Personal Social Services Research Unit, University of Kent at Canterbury, Canterbury, UK, 2001.
   Google Scholar
• British National Formulary No 42. London, British Medical Association and Royal Pharmaceutical Society of Great Britain, 2001.
   Google Scholar
• Department of Health and Human Services. National Ambulatory Medical Care Survey (NAMCS). National Centre for Health Statistics (NCHS). 1997.
   Google Scholar
• Husereau DR, Brady B, McGeer A. Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment. Technology Report no. 21. 2001. Ottawa, Canadian Coordinating Office for Health Technology Assessment.
   Google Scholar
• Aoki FY, Macleod MD, Paggiaro P et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. Journal of Antimicrobial Chemotherapy 2003; 51: 123–129.
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Hayden FG, Reisinger KS. Oral oseltamivir treatment of influenza in children. Pediatric Infectious Disease Journal 2001; 20: 127–133.
   PubMed Web of Science ®Google Scholar